NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

$73.70 -0.74 (-0.99 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$73.70

Today's Range$73.18 - $74.42

52-Week Range$63.76 - $89.54

Volume5.19 million shs

Average Volume5.77 million shs

Market Capitalization$97.06 billion

P/E Ratio8.61

Dividend Yield3.06%

Beta1.19

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:GILD

CUSIP37555810

Webwww.gilead.com

Phone650-574-3000

Debt

Debt-to-Equity Ratio1.53%

Current Ratio2.74%

Quick Ratio2.67%

Price-To-Earnings

Trailing P/E Ratio8.61

Forward P/E Ratio11.66

P/E Growth-1.68

Sales & Book Value

Annual Sales$26.11 billion

Price / Sales3.68

Cash Flow$9.5220 per share

Price / Cash7.74

Book Value$15.69 per share

Price / Book4.70

Profitability

EPS (Most Recent Fiscal Year)$8.56

Net Income$4.63 billion

Net Margins17.73%

Return on Equity50.29%

Return on Assets17.85%

Miscellaneous

Employees10,000

Outstanding Shares1,303,850,000

How to Become a New Pot Stock Millionaire

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Tuesday, February 6th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share on Thursday, March 29th. This represents a $2.28 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.52. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences (NASDAQ:GILD) issued its quarterly earnings results on Tuesday, February, 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.11. The biopharmaceutical company earned $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company's revenue for the quarter was down 18.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.70 earnings per share. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

26 brokerages have issued 1-year price objectives for Gilead Sciences' shares. Their predictions range from $73.77 to $105.00. On average, they expect Gilead Sciences' share price to reach $88.7033 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

1. According to Zacks Investment Research, "Gilead’s HIV franchise continues to gain traction, courtesy of the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 62% of total HIV prescription volume following the launch of Genvoya, Odefsey and Descovy in 2016. The approval of Gilead’s latest triple HIV therapy, Biktarvy, is likely to provide an impetus to the stock as Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy post Kite acquisition. Shares of the company have outperformed the industry in the last twelve months. However, the HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Both pricing and market share are expected to stabilize by mid-2018 while patient starts are expected to decline further." (4/19/2018)
2. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
3. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
4. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest in March. As of March 29th, there was short interest totalling 18,219,703 shares, a drop of 9.1% from the March 15th total of 20,048,876 shares. Based on an average daily volume of 7,317,354 shares, the days-to-cover ratio is currently 2.5 days. Approximately 1.4% of the shares of the company are short sold.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), AveXis (AVXS), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Acceleron Pharma (XLRN) and Editas Medicine (EDIT).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

Dr. John F. Milligan Ph.D., Pres, CEO & Director (Age 57)
Ms. Robin L. Washington, Chief Financial Officer and Exec. VP (Age 55)
Dr. Norbert W. Bischofberger, Exec. VP of R&D and Chief Scientific Officer (Age 62)
Mr. Kevin B. Young, Chief Operating Officer (Age 60)
Mr. Gregg H. Alton, Exec. VP of Corp. & Medical Affairs and Interim Head of International Commercial Operations (Age 52)

Has Gilead Sciences been receiving favorable news coverage?

Media coverage about GILD stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.07 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.39 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $73.70.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $97.06 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		1,691 (Vote Outperform)
Underperform Votes:		643 (Vote Underperform)
Total Votes:		2,334

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Gilead Sciences (NASDAQ:GILD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

26 Wall Street analysts have issued ratings and price targets for Gilead Sciences in the last 12 months. Their average twelve-month price target is $88.7033, suggesting that the stock has a possible upside of 20.36%. The high price target for GILD is $105.00 and the low price target for GILD is $73.77. There are currently 9 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.65	2.65	2.57	2.57
Ratings Breakdown:	0 Sell Rating(s) 9 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 9 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 12 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 12 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$88.7033	$88.7033	$85.4071	$85.4348
Price Target Upside:	20.36% upside	12.07% upside	8.08% upside	4.71% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Credit Suisse Group	Set Price Target	Hold	$80.00	Low
3/6/2018	Barclays	Reiterated Rating	Overweight -> Overweight	$90.00 -> $95.00	Low
2/23/2018	Royal Bank of Canada	Reiterated Rating	Buy	$94.00	Low
2/22/2018	Leerink Swann	Reiterated Rating	Mkt Perform -> Market Perform	$83.00 -> $80.00	Low
2/12/2018	Mizuho	Reiterated Rating	Buy -> Buy	$83.00 -> $95.00	Low
2/8/2018	BMO Capital Markets	Boost Price Target	Outperform -> Market Perform	$86.00 -> $88.00	High
2/8/2018	Citigroup	Reiterated Rating	Buy -> Buy	$103.00 -> $105.00	High
2/7/2018	Morgan Stanley	Lower Price Target	Equal Weight -> Equal Weight	$87.00 -> $84.00	Medium
2/7/2018	Bank of America	Boost Price Target	Neutral -> Neutral	$82.00 -> $87.00	Medium
2/6/2018	Maxim Group	Set Price Target	Buy	$94.00	High
1/26/2018	Jefferies Group	Upgrade	Hold -> Buy	$81.19 -> $93.00	High
1/16/2018	Wells Fargo	Upgrade	Market Perform -> Outperform	$79.02 -> $96.00	Low
12/21/2017	Oppenheimer	Reiterated Rating	Hold		Medium
11/13/2017	Argus	Downgrade	Buy -> Hold	$73.25 -> $73.77	N/A
10/25/2017	JPMorgan Chase	Set Price Target	Buy	$85.00	N/A
10/19/2017	William Blair	Reiterated Rating	Buy		N/A
10/19/2017	Berenberg Bank	Set Price Target	Buy	$96.00	N/A
10/5/2017	CIBC	Initiated Coverage	Market Perform -> Market Perform		N/A
8/31/2017	Cowen	Reiterated Rating	Outperform	$90.00	Medium
8/31/2017	Deutsche Bank	Reiterated Rating	Buy	$81.00	Medium
8/29/2017	Robert W. Baird	Reiterated Rating	Outperform	$87.00	Low
8/28/2017	Needham & Company LLC	Reiterated Rating	Hold		Low
7/26/2017	Redburn Partners	Initiated Coverage	Buy		Medium
5/3/2017	Gabelli	Reiterated Rating	Buy	$85.00	Medium
5/3/2017	Stifel Nicolaus	Reiterated Rating	Buy	$87.00	Medium
4/21/2017	Piper Jaffray	Reiterated Rating	Buy		Low
3/13/2017	Goldman Sachs	Reiterated Rating	Neutral	$70.00 -> $68.00	Low
3/9/2017	UBS	Reiterated Rating	Neutral -> Neutral	$118.00 -> $72.00	N/A
10/15/2016	Evercore ISI	Set Price Target	Buy	$90.00	N/A
7/27/2016	S&P Equity Research	Reiterated Rating	Strong-Buy		N/A

(Data available from 4/21/2016 forward)

Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2018 EPS Consensus Estimate: $6.29

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$1.55	$1.79	$1.67
Q2 2018	3	$1.46	$1.69	$1.60
Q3 2018	3	$1.38	$1.66	$1.54
Q4 2018	3	$1.31	$1.66	$1.48

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/30/2018		$1.64					N/A
2/6/2018	Q4 2017	$1.67	$1.78	$5.7118 billion	$5.9490 billion	View	Listen
10/26/2017	Q3 2017	$2.13	$2.27	$6.3970 billion	$6.5120 billion	View	N/A
7/26/2017	Q2 2017	$2.11	$2.56	$6.3503 billion	$7.1410 billion	View	N/A
5/2/2017	Q1 2017	$2.18	$2.20	$6.6604 billion	$6.5050 billion	View	Listen
2/7/2017	Q416	$2.61	$2.70	$7.16 billion	$7.30 billion	View	Listen
11/1/2016	Q316	$2.87	$2.75	$7.47 billion	$7.40 billion	View	Listen
7/25/2016	Q216	$3.02	$3.08	$7.80 billion	$7.78 billion	View	Listen
4/28/2016	Q116	$3.13	$3.03	$8.08 billion	$7.80 billion	View	Listen
2/2/2016	Q415	$3.00	$3.32	$8.11 billion	$8.51 billion	View	Listen
10/27/2015	Q315	$2.87	$3.22	$7.84 billion	$8.30 billion	View	Listen
7/28/2015	Q215	$2.83	$3.15	$7.60 billion	$8.2240 billion	View	Listen
4/30/2015	Q115	$2.78	$2.94	$6.81 billion	$7.59 billion	View	Listen
2/3/2015	Q414	$2.27	$2.43	$6.68 million	$7.3140 billion	View	Listen
10/28/2014	Q314	$1.92	$1.84	$5.99 billion	$6.04 billion	View	Listen
7/23/2014	Q214	$1.61	$2.36	$5.68 billion	$6.53 billion	View	Listen
4/22/2014	Q114	$0.75	$1.48	$3.80 billion	$4.9990 billion	View	Listen
2/4/2014	Q413	$0.50	$0.55	$2.85 billion	$3.04 billion	View	Listen
10/29/2013	Q313	$0.48	$0.52	$2.72 billion	$2.7828 billion	View	Listen
7/25/2013	Q2 2013	$0.50	$0.50	$2.66 billion	$2.77 billion	View	Listen
5/2/2013	Q1 2013	$0.50	$0.48	$2.5687 billion	$2.5316 billion	View	Listen
2/4/2013	Q4 2012	$0.48	$0.50	$2.43 billion	$2.5880 billion	View	Listen
10/23/2012		$0.94	$1.00			View	N/A
7/26/2012		$0.95	$0.99			View	N/A
4/26/2012		$0.94	$0.91			View	N/A
2/2/2012		$1.04	$0.97			View	N/A
10/27/2011		$1.01	$1.02			View	N/A
7/26/2011	Q2 2011	$0.48	$0.47			View	N/A
4/20/2011		$0.97	$0.87			View	N/A
1/25/2011		$0.95	$0.95			View	N/A
10/19/2010	Q3 2010	$0.42	$0.43			View	N/A
7/20/2010	Q2 2010	$0.41	$0.40			View	N/A
4/20/2010	Q1 2010	$0.46	$0.47			View	N/A
1/26/2010	Q4 2009	$0.41	$0.45			View	N/A
10/20/2009	Q3 2009	$0.35	$0.37			View	N/A
7/21/2009	Q2 2009	$0.31	$0.33			View	N/A
4/21/2009	Q1 2009	$0.30	$0.32			View	N/A
1/27/2009	Q4 2008	$0.28	$0.30			View	N/A
10/16/2008	Q3 2008	$0.25	$0.26			View	N/A
7/17/2008	Q2 2008	$0.25	$0.23			View	N/A
4/16/2008	Q1 2008	$0.24	$0.26			View	N/A
1/23/2008	Q4 2007	$0.21	$0.21			View	N/A

(Earnings results data provided by Zacks Investment Research)

Gilead Sciences (NASDAQ:GILD) Dividend Information

Gilead Sciences pays an annual dividend of $2.28 per share, with a dividend yield of 3.09%. GILD's most recent quarterly dividend payment was Thursday, March 29. Gilead Sciences pays out 26.64% of its earnings out as a dividend.

Most Recent Dividend:	3/29/2018
Annual Dividend:	$2.28
Dividend Yield:	3.09%
Payout Ratio:	26.64% (Trailing 12 Months of Earnings) 36.08% (Based on This Year's Estimates) 37.94% (Based on Next Year's Estimates)

Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2018	quarterly	$0.57	3.02%	3/15/2018	3/16/2018	3/29/2018
10/26/2017	quarterly	$0.52	2.7%	12/14/2017	12/15/2017	12/28/2017
7/26/2017	quarterly	$0.52	2.78%	9/14/2017	9/15/2017	9/28/2017
5/2/2017	quarterly	$0.52	3.09%	6/14/2017	6/16/2017	6/29/2017
2/7/2017	quarterly	$0.52	3.11%	3/14/2017	3/16/2017	3/30/2017
11/1/2016	quarterly	$0.47	2.59%	12/13/2016	12/15/2016	12/29/2016
7/25/2016	quarterly	$0.47	2.32%	9/14/2016	9/16/2016	9/29/2016
4/28/2016	quarterly	$0.47	2.13%	6/14/2016	6/16/2016	6/29/2016
2/2/2016	quarterly	$0.43	1.99%	3/14/2016	3/16/2016	3/30/2016
10/27/2015	quarterly	$0.43	1.59%	12/14/2015	12/16/2015	12/30/2015
7/28/2015	quarterly	$0.43	1.49%	9/14/2015	9/16/2015	9/29/2015
4/30/2015	quarterly	$0.43		6/12/2015	6/16/2015	6/29/2015

(Data available from 1/1/2013 forward)

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 78.35%

Insider Trading History for Gilead Sciences (NASDAQ:GILD)

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/13/2018	John Francis Cogan	Director	Sell	5,833	$75.56	$440,741.48	58,452
4/6/2018	John Francis Cogan	Director	Sell	5,833	$74.47	$434,383.51	58,452
4/2/2018	John C Martin	Director	Sell	50,000	$73.14	$3,657,000.00	3,067,762
3/23/2018	John Francis Cogan	Director	Sell	5,833	$75.02	$437,591.66	58,452
3/16/2018	John Francis Cogan	Director	Sell	5,833	$80.09	$467,164.97	58,452
3/12/2018	John Francis Cogan	Director	Sell	5,833	$80.93	$472,064.69
3/1/2018	Gregg H Alton	EVP	Sell	25,000	$78.69	$1,967,250.00	69,426
3/1/2018	John C Martin	Chairman	Sell	50,000	$78.65	$3,932,500.00	3,067,762
2/28/2018	Robin L Washington	CFO	Sell	5,000	$80.31	$401,550.00	23,749
2/20/2018	Gregg H Alton	EVP	Sell	14,435	$81.54	$1,177,029.90
2/9/2018	Gayle E Wilson	Director	Sell	60,000	$77.92	$4,675,200.00	182,258
2/1/2018	Gregg H Alton	EVP	Sell	25,000	$83.51	$2,087,750.00	62,738
2/1/2018	John C Martin	Chairman	Sell	50,000	$83.56	$4,178,000.00	3,046,766
1/16/2018	James R Meyers	EVP	Sell	100,000	$80.24	$8,024,000.00	102,715
1/11/2018	Gregg H Alton	EVP	Sell	30,000	$79.00	$2,370,000.00	57,114
1/2/2018	Gregg H Alton	EVP	Sell	15,000	$73.87	$1,108,050.00	64,613
1/2/2018	John C Martin	Insider	Sell	50,000	$73.62	$3,681,000.00	3,046,766
12/1/2017	Gregg H Alton	EVP	Sell	15,000	$74.64	$1,119,600.00	70,988
12/1/2017	John C Martin	Insider	Sell	73,333	$74.98	$5,498,508.34	3,070,099
11/13/2017	John F Milligan	Insider	Sell	220,000	$72.88	$16,033,600.00
11/1/2017	Gregg H Alton	EVP	Sell	15,000	$74.82	$1,122,300.00	77,363
11/1/2017	John C Martin	Insider	Sell	73,333	$75.13	$5,509,508.29	3,070,099
10/2/2017	Gregg H Alton	EVP	Sell	25,000	$82.65	$2,066,250.00
10/2/2017	John C Martin	Insider	Sell	73,333	$82.56	$6,054,372.48
9/7/2017	Robin L Washington	CFO	Sell	51,820	$85.00	$4,404,700.00	43,352
9/1/2017	Gregg H Alton	EVP	Sell	25,000	$83.05	$2,076,250.00	101,488
9/1/2017	John C Martin	Insider	Sell	73,333	$83.11	$6,094,705.63	2,996,766
8/31/2017	James R Meyers	EVP	Sell	60,000	$83.19	$4,991,400.00	62,715
8/30/2017	Gregg H Alton	EVP	Sell	50,000	$79.00	$3,950,000.00	113,237
8/1/2017	Gregg H Alton	EVP	Sell	15,000	$75.88	$1,138,200.00	106,113
8/1/2017	John C Martin	Insider	Sell	73,333	$75.86	$5,563,041.38	3,199,969
7/21/2017	Gregg H Alton	EVP	Sell	40,000	$74.00	$2,960,000.00	137,488
7/3/2017	Gregg H Alton	EVP	Sell	5,000	$71.06	$355,300.00	102,988
7/3/2017	John C Martin	Insider	Sell	73,333	$71.00	$5,206,643.00	3,199,969
5/9/2017	John Francis Cogan	Director	Sell	9,943	$67.25	$668,666.75	47,562
4/3/2017	John C Martin	Insider	Sell	73,333	$67.18	$4,926,510.94	3,199,969
3/30/2017	Gregg H Alton	EVP	Sell	5,000	$67.48	$337,400.00	117,988
1/3/2017	John C Martin	Insider	Sell	73,337	$73.59	$5,396,869.83	3,204,433
11/18/2016	John W Madigan	Director	Sell	105,000	$74.86	$7,860,300.00	121,761
10/3/2016	John C Martin	Insider	Sell	100,000	$77.63	$7,763,000.00	3,231,096
9/22/2016	Gregg H Alton	EVP	Sell	5,000	$81.84	$409,200.00	132,964
9/6/2016	John F Milligan	Insider	Sell	70,000	$77.74	$5,441,800.00	1,128,963
9/1/2016	John C Martin	Insider	Sell	100,000	$77.48	$7,748,000.00	3,287,810
8/24/2016	Kevin E Lofton	Director	Sell	3,500	$81.97	$286,895.00
8/1/2016	John C Martin	Insider	Sell	100,000	$80.50	$8,050,000.00	4,119,727
8/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$79.81	$159,620.00	64,122
7/5/2016	John F Milligan	CEO	Sell	112,000	$84.33	$9,444,960.00	1,170,963
7/1/2016	John C Martin	Chairman	Sell	100,000	$84.73	$8,473,000.00	4,119,727
7/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$83.12	$166,240.00	63,122
6/6/2016	John F Milligan	CEO	Sell	112,000	$86.94	$9,737,280.00	1,170,963
6/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$87.02	$174,040.00	63,122
5/2/2016	John C Martin	Chairman	Sell	100,000	$87.82	$8,782,000.00	4,119,727
5/2/2016	John F Milligan	CEO	Sell	112,000	$87.71	$9,823,520.00	1,170,963
5/2/2016	Paul Rutherford Carter	EVP	Sell	2,000	$88.72	$177,440.00	62,939
4/19/2016	Gregg H Alton	EVP	Sell	40,000	$100.01	$4,000,400.00	177,964
4/4/2016	John F Milligan	CEO	Sell	112,000	$94.59	$10,594,080.00	1,170,963
4/1/2016	John C Martin	Chairman	Sell	100,000	$93.24	$9,324,000.00	4,119,727
4/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$91.34	$182,680.00	63,122
3/14/2016	Gregg H Alton	EVP	Sell	5,000	$90.00	$450,000.00	147,090
2/26/2016	Gayle E Wilson	Director	Sell	6,650	$90.61	$602,556.50	110,523
2/1/2016	John C. Martin	CEO	Sell	100,000	$83.42	$8,342,000.00	3,948,066
2/1/2016	Paul Rutherford Carter	EVP	Sell	2,000	$82.32	$164,640.00	48,783
1/4/2016	John C. Martin	CEO	Sell	100,000	$97.68	$9,768,000.00	3,948,066
1/4/2016	Paul Rutherford Carter	EVP	Sell	2,000	$99.20	$198,400.00	48,783
12/15/2015	Norbert W. Bischofberger	EVP	Sell	70,000	$102.41	$7,168,700.00	127,936
12/7/2015	John F. Milligan	COO	Sell	100,000	$103.18	$10,318,000.00	1,029,108
11/24/2015	John Francis Cogan	Director	Sell	15,000	$105.95	$1,589,250.00	44,309
11/2/2015	Gregg H. Alton	EVP	Sell	12,000	$109.38	$1,312,560.00	131,422
11/2/2015	John C. Martin	CEO	Sell	150,000	$109.42	$16,413,000.00	3,948,066
11/2/2015	Robin L Washington	CFO	Sell	6,250	$109.46	$684,125.00
10/27/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00	44,309
10/26/2015	Gregg H. Alton	EVP	Sell	5,000	$110.00	$550,000.00	133,422
10/26/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00	44,309
10/15/2015	Norbert W. Bischofberger	EVP	Sell	70,000	$100.05	$7,003,500.00	165,168
10/7/2015	John F. Milligan	COO	Sell	100,000	$99.22	$9,922,000.00	1,029,108
10/5/2015	Gregg H. Alton	EVP	Sell	5,000	$100.00	$500,000.00	133,422
10/1/2015	John C. Martin	CEO	Sell	150,000	$97.48	$14,622,000.00	3,948,066
10/1/2015	Paul Rutherford Carter	EVP	Sell	2,000	$98.59	$197,180.00	48,783
9/15/2015	Gregg H. Alton	EVP	Sell	5,000	$110.00	$550,000.00	135,422
9/15/2015	John Francis Cogan	Director	Sell	15,000	$110.00	$1,650,000.00	44,309
9/8/2015	John F. Milligan	COO	Sell	100,000	$103.39	$10,339,000.00	1,029,108
9/2/2015	Robin L Washington	CFO	Sell	6,250	$102.20	$638,750.00
9/1/2015	John C. Martin	CEO	Sell	150,000	$102.73	$15,409,500.00	3,948,066
8/28/2015	Gayle E. Wilson	Director	Sell	21,000	$106.96	$2,246,160.00	101,769
8/25/2015	John C. Martin	CEO	Sell	133,213	$105.17	$14,010,011.21	3,948,066
8/17/2015	Norbert W Bischofberger	EVP	Sell	70,000	$116.16	$8,131,200.00
7/7/2015	John F Milligan	COO	Sell	100,000	$114.44	$11,444,000.00
6/26/2015	John Francis Cogan	Director	Sell	27,000	$120.13	$3,243,510.00
6/18/2015	Paul Rutherford Carter	EVP	Sell	10,000	$120.00	$1,200,000.00
6/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$117.67	$8,236,900.00
6/8/2015	John F Milligan	COO	Sell	100,000	$114.05	$11,405,000.00
6/1/2015	Gregg H Alton	EVP	Sell	17,000	$113.64	$1,931,880.00
6/1/2015	John C Martin	CEO	Sell	150,000	$113.95	$17,092,500.00
4/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$103.84	$7,268,800.00
4/8/2015	Paul Rutherford Carter	EVP	Sell	1,000	$100.00	$100,000.00
4/1/2015	Gregg H Alton	EVP	Sell	7,000	$96.53	$675,710.00
4/1/2015	John C Martin	CEO	Sell	150,000	$96.74	$14,511,000.00
3/2/2015	John C Martin	CEO	Sell	150,000	$103.51	$15,526,500.00
3/2/2015	Paul Rutherford Carter	EVP	Sell	2,000	$104.18	$208,360.00
3/2/2015	Richard James Whitley	Director	Sell	5,000	$103.43	$517,150.00
2/6/2015	Olsen Per Wold	Director	Buy	10,000	$99.92	$999,200.00
2/2/2015	Gregg H Alton	EVP	Sell	12,000	$105.73	$1,268,760.00
2/2/2015	John C Martin	CEO	Sell	150,000	$105.43	$15,814,500.00
2/2/2015	Robin L Washington	CFO	Sell	33,192	$105.38	$3,497,772.96
1/15/2015	Norbert W Bischofberger	EVP	Sell	70,000	$98.47	$6,892,900.00
1/8/2015	Gregg H Alton	EVP	Sell	5,000	$100.89	$504,450.00
1/5/2015	John C Martin	CEO	Sell	150,000	$95.12	$14,268,000.00
1/2/2015	Gregg H Alton	EVP	Sell	7,000	$95.17	$666,190.00
1/2/2015	Richard James Whitley	Director	Sell	5,000	$95.22	$476,100.00
12/22/2014	John Francis Cogan	Director	Sell	26,000	$95.03	$2,470,780.00
12/8/2014	John F Milligan	COO	Sell	146,823	$106.26	$15,601,411.98
12/1/2014	John C Martin	CEO	Sell	140,633	$100.72	$14,164,555.76
12/1/2014	Paul Rutherford Carter	EVP	Sell	2,000	$100.02	$200,040.00
11/3/2014	John C Martin	CEO	Sell	140,625	$110.40	$15,525,000.00
11/3/2014	Richard James Whitley	Director	Sell	5,000	$112.02	$560,100.00
11/3/2014	Robin L Washington	CFO	Sell	33,192	$110.26	$3,659,749.92
10/24/2014	Paul Rutherford Carter	EVP	Sell	2,000	$110.00	$220,000.00
10/7/2014	John F Milligan	COO	Sell	146,895	$104.60	$15,365,217.00
10/1/2014	John C Martin	CEO	Sell	140,625	$105.91	$14,893,593.75
10/1/2014	Paul Rutherford Carter	EVP	Sell	2,000	$106.39	$212,780.00
10/1/2014	Richard James Whitley	Director	Sell	5,000	$106.99	$534,950.00
9/26/2014	Paul Rutherford Carter	EVP	Sell	2,000	$107.47	$214,940.00
9/22/2014	John Francis Cogan	Director	Sell	5,000	$106.60	$533,000.00
9/8/2014	John F Milligan	COO	Sell	146,895	$105.99	$15,569,401.05
9/2/2014	Gregg H Alton	EVP	Sell	33,000	$108.58	$3,583,140.00
9/2/2014	John C Martin	CEO	Sell	140,625	$108.64	$15,277,500.00
8/26/2014	Paul Rutherford Carter	EVP	Sell	10,000	$106.16	$1,061,600.00
8/25/2014	Robin L Washington	CFO	Sell	4,304	$105.87	$455,664.48
8/21/2014	John Francis Cogan	Director	Sell	5,000	$101.09	$505,450.00
8/14/2014	Robin L Washington	CFO	Sell	33,556	$95.56	$3,206,611.36
8/1/2014	Gregg H Alton	EVP	Sell	33,000	$91.62	$3,023,460.00
8/1/2014	John C Martin	CEO	Sell	140,625	$91.53	$12,871,406.25
8/1/2014	Richard James Whitley	Director	Sell	5,000	$91.00	$455,000.00
8/1/2014	Robin L Washington	CFO	Sell	30,600	$91.48	$2,799,288.00
7/28/2014	Nicholas G Moore	Director	Sell	45,000	$90.56	$4,075,200.00
7/21/2014	John Francis Cogan	Director	Sell	5,000	$89.67	$448,350.00
7/8/2014	Paul Rutherford Carter	EVP	Sell	16,728	$86.45	$1,446,135.60
7/1/2014	Gregg H Alton	EVP	Sell	33,000	$84.12	$2,775,960.00
7/1/2014	John C Martin	CEO	Sell	140,625	$84.84	$11,930,625.00
7/1/2014	Richard James Whitley	Director	Sell	5,000	$83.65	$418,250.00
6/30/2014	Robin L Washington	CFO	Sell	10,400	$83.98	$873,392.00
6/23/2014	John Francis Cogan	Director	Sell	5,000	$81.82	$409,100.00
6/16/2014	Norbert W Bischofberger	EVP	Sell	90,000	$80.90	$7,281,000.00
6/9/2014	Paul Rutherford Carter	EVP	Sell	16,728	$79.43	$1,328,705.04
6/4/2014	Robin L Washington	CFO	Sell	6,426	$82.52	$530,273.52
6/2/2014	Gregg H Alton	EVP	Sell	33,000	$81.35	$2,684,550.00
6/2/2014	Richard James Whitley	Director	Sell	5,000	$80.95	$404,750.00
5/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$80.65	$7,258,500.00	119,302
5/6/2014	Robin Washington	CFO	Sell	3,000	$79.91	$239,730.00	49,832
5/1/2014	Gregg Alton	EVP	Sell	13,000	$79.08	$1,028,040.00	130,694
5/1/2014	John Martin	CEO	Sell	140,625	$79.02	$11,112,187.50	4,429,387
5/1/2014	Richard James Whitley	Director	Sell	5,000	$78.63	$393,150.00	12,778
5/1/2014	Robin Washington	CFO	Sell	27,600	$79.16	$2,184,816.00	49,832
4/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$67.03	$6,032,700.00	119,302
4/8/2014	John Francis Cogan	Director	Sell	5,000	$70.55	$352,750.00	39,542
4/8/2014	Paul Rutherford Carter	EVP	Sell	16,728	$70.53	$1,179,825.84	28,562
4/1/2014	Gregg Alton	EVP	Sell	13,000	$73.20	$951,600.00	132,694
4/1/2014	John Martin	CEO	Sell	140,625	$73.26	$10,302,187.50	4,429,387
3/14/2014	John Francis Cogan	Director	Sell	14,000	$76.44	$1,070,160.00	39,542
3/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$75.89	$6,830,100.00	119,302
3/10/2014	Paul Rutherford Carter	EVP	Sell	16,728	$79.32	$1,326,864.96	28,562
3/3/2014	Gregg Alton	EVP	Sell	33,000	$81.84	$2,700,720.00	84,484
3/3/2014	John Martin	CEO	Sell	140,625	$81.74	$11,494,687.50	4,257,235
2/26/2014	Nicholas Moore	Director	Sell	20,000	$84.05	$1,681,000.00
2/19/2014	Nicholas Moore	Director	Sell	19,068	$83.12	$1,584,932.16
1/23/2014	Kevin Young	EVP	Sell	100,000	$81.44	$8,144,000.00	216,418
1/21/2014	Gregg Alton	EVP	Sell	120,000	$80.00	$9,600,000.00	32,938
1/14/2014	Norbert Bischofberger	EVP	Sell	90,000	$74.23	$6,680,700.00
10/23/2013	Kevin Young	EVP	Sell	75,000	$68.56	$5,142,000.00
10/14/2013	Norbert Bischofberger	EVP	Sell	90,000	$62.54	$5,628,600.00	2,159,643
9/23/2013	Kevin Young	EVP	Sell	100,000	$62.88	$6,288,000.00	161,840
9/16/2013	Norbert Bischofberger	EVP	Sell	90,000	$63.11	$5,679,900.00	2,159,643
9/3/2013	Gregg Alton	EVP	Sell	30,000	$60.99	$1,829,700.00	46,938
9/3/2013	John Martin	CEO	Sell	282,242	$60.97	$17,208,294.74	4,057,121
8/30/2013	Nicholas Moore	Director	Sell	151,720	$60.42	$9,166,922.40
8/14/2013	Norbert Bischofberger	EVP	Sell	90,000	$58.77	$5,289,300.00	2,159,643
8/1/2013	Gregg H Alton	EVP	Sell	30,000	$61.49	$1,844,700.00
8/1/2013	John C Martin	CEO	Sell	282,242	$61.61	$17,388,929.62
7/30/2013	John W Madigan	Director	Sell	249,000	$61.97	$15,430,530.00
7/15/2013	Norbert W Bischofberger	EVP	Sell	90,000	$57.33	$5,159,700.00
7/2/2013	John Francis Cogan	Director	Sell	17,000	$51.66	$878,220.00
7/1/2013	Gregg H Alton	EVP	Sell	30,000	$52.09	$1,562,700.00
7/1/2013	John C Martin	CEO	Sell	282,242	$52.00	$14,676,584.00
7/1/2013	Robin L Washington	CFO	Sell	45,600	$52.01	$2,371,656.00
6/7/2013	John Francis Cogan	Director	Sell	110,000	$52.15	$5,736,500.00
6/3/2013	Gregg H Alton	EVP	Sell	30,000	$52.77	$1,583,100.00
6/3/2013	John C Martin	CEO	Sell	282,242	$52.84	$14,913,667.28
2/28/2013	Olsen Per Wold	Director	Buy	10,000	$43.05	$430,500.00
12/3/2012	Gregg H Alton	EVP	Sell	44,000	$75.10	$3,304,400.00
12/3/2012	John C Martin	CEO	Sell	291,000	$75.01	$21,827,910.00
11/12/2012	Robin L Washington	CFO	Sell	55,950	$73.11	$4,090,504.50
10/3/2012	John F Milligan	COO	Sell	140,000	$69.85	$9,779,000.00
10/2/2012	Robin L Washington	CFO	Sell	29,500	$68.62	$2,024,290.00
9/4/2012	Gregg H Alton	EVP	Sell	44,000	$57.50	$2,530,000.00

(Data available from 1/1/2013 forward)

Gilead Sciences (NASDAQ GILD) News Headlines

Source:

Date	Headline
	Gilead Sciences' (GILD) "Buy" Rating Reaffirmed at Jefferies Group www.americanbankingnews.com - April 19 at 10:12 PM
	Gilead Sciences (GILD) Given Overweight Rating at JPMorgan Chase www.americanbankingnews.com - April 19 at 10:12 PM
	Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug finance.yahoo.com - April 19 at 3:10 PM
	Gilead Sciences' (GILD) Equal Weight Rating Reiterated at Morgan Stanley www.americanbankingnews.com - April 19 at 2:58 PM
	Gilead Sciences (GILD) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 19 at 11:46 AM
	Q1 2018 EPS Estimates for Gilead Sciences (GILD) Lifted by Leerink Swann www.americanbankingnews.com - April 19 at 7:08 AM
	Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company finance.yahoo.com - April 19 at 5:16 AM
	Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics finance.yahoo.com - April 18 at 3:10 PM
	AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane finance.yahoo.com - April 18 at 3:10 PM
	Why Big Biotech Stocks May Get An Earnings Boost finance.yahoo.com - April 18 at 3:10 PM
	Big Biotech ETF Can Bounce Back finance.yahoo.com - April 18 at 3:10 PM
	Gilead Sciences (GILD) Given a $80.00 Price Target by Credit Suisse Group Analysts www.americanbankingnews.com - April 18 at 9:22 AM
	FY2020 EPS Estimates for Gilead Sciences Increased by Leerink Swann (GILD) www.americanbankingnews.com - April 18 at 8:56 AM
	Q1 2018 Earnings Forecast for Gilead Sciences (GILD) Issued By William Blair www.americanbankingnews.com - April 18 at 7:55 AM
	Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018 finance.yahoo.com - April 18 at 5:07 AM
	Gilead Sciences (GILD) Downgraded to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 17 at 5:27 PM
	Gilead Sciences (GILD) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 16 at 8:40 PM
	Gilead Sciences (GILD) Director Sells $440,741.48 in Stock www.americanbankingnews.com - April 16 at 7:14 PM
	Gilead (GILD) Presents Encouraging Data on NASH Therapies finance.yahoo.com - April 16 at 3:18 PM
	How AbbVie Performed in 4Q17 and Fiscal 2017 finance.yahoo.com - April 16 at 3:18 PM
	Gilead Sciences' (GILD) Hold Rating Reiterated at Maxim Group www.americanbankingnews.com - April 15 at 4:33 PM
	Gilead Sciences (GILD) PT Set at $85.00 by JPMorgan Chase www.americanbankingnews.com - April 15 at 4:33 PM
	Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International ... www.businesswire.com - April 14 at 5:02 AM
	Gilead (GILD) Presents Data on Multiple Investigational Regimens for Treatment of NASH and Advanced Fibrosis at The International Liver Congress www.streetinsider.com - April 14 at 5:02 AM
	3 Top Healthcare Stocks to Buy in April finance.yahoo.com - April 14 at 5:02 AM
	Gilead Sciences (GILD) Upgraded at BidaskClub www.americanbankingnews.com - April 14 at 12:49 AM
	Gilead combo therapy for NASH shows encouraging action in proof-of-concept study seekingalpha.com - April 13 at 3:12 PM
	Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic ... www.businesswire.com - April 13 at 3:12 PM
	Is Gilead Sciences, Inc. (GILD) a Buy? www.fool.com - April 13 at 3:12 PM
	Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018 finance.yahoo.com - April 13 at 3:12 PM
	Why One Drug Flop Tanked Incyte's Stock finance.yahoo.com - April 13 at 5:03 AM
	[$$] How Big Biotech Can Win Back Investors finance.yahoo.com - April 13 at 5:03 AM
	Brokerages Expect Gilead Sciences (GILD) Will Post Quarterly Sales of $5.37 Billion www.americanbankingnews.com - April 13 at 3:48 AM
	Gilead Sciences (GILD) Sees Significant Decline in Short Interest www.americanbankingnews.com - April 13 at 3:43 AM
	Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' finance.yahoo.com - April 12 at 3:08 PM
	Silicon Valley’s 10 highest-paid CEOs may not be who you'd expect finance.yahoo.com - April 12 at 3:08 PM
	Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' finance.yahoo.com - April 12 at 5:15 AM
	BidaskClub Downgrades Gilead Sciences (GILD) to Hold www.americanbankingnews.com - April 11 at 10:10 PM
	This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous www.msn.com - April 11 at 3:13 PM
	This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous finance.yahoo.com - April 11 at 3:13 PM
	Gilead Sciences (GILD) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - April 11 at 11:37 AM
	Gilead Sciences (GILD) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 11 at 10:27 AM
	Zacks: Brokerages Expect Gilead Sciences (GILD) to Post $1.61 EPS www.americanbankingnews.com - April 11 at 9:17 AM
	Gilead Sciences Stock Performance in 1Q18 finance.yahoo.com - April 11 at 5:02 AM
	'Safer' Dividend Healthcare Top Gainers Are AbbVie, Sanofi, Lilly, Gilead, And Novartis (All BPh) Per Broker Targets To April 2019 seekingalpha.com - April 10 at 3:01 PM
	Credit Suisse Group Reaffirms "Outperform" Rating for Gilead Sciences (GILD) www.americanbankingnews.com - April 9 at 7:30 PM
	Gilead Sciences (GILD) Director John Francis Cogan Sells 5,833 Shares www.americanbankingnews.com - April 9 at 7:16 PM
	Wells Fargo Boosts Gilead Sciences (GILD) Price Target to $81.00 www.americanbankingnews.com - April 9 at 12:10 PM
	Vetr Upgrades Gilead Sciences (GILD) to Buy www.americanbankingnews.com - April 9 at 11:02 AM
	Gilead Sciences' (GILD) "Overweight" Rating Reiterated at Barclays www.americanbankingnews.com - April 7 at 12:13 PM

Gilead Sciences (NASDAQ:GILD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement

Gilead Sciences (NASDAQ GILD) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff